SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
Business
Panbela Provides Business Update and Reports Q1 2023 Financial Results
May 4, 2023
 · 
12 min read
Business
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
April 24, 2023
 · 
6 min read
BioMidwest
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
April 19, 2023
 · 
8 min read
Drug Development
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
April 12, 2023
 · 
8 min read
BioMidwest
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
April 11, 2023
 · 
9 min read
BioMidwest
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
April 10, 2023
 · 
6 min read
BioMidwest
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
April 6, 2023
 · 
6 min read
BioMidwest
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
April 3, 2023
 · 
6 min read
BioMidwest
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
March 22, 2023
 · 
8 min read
Business
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
March 16, 2023
 · 
13 min read
Load More
JOBS